Therapeutic options for malignant ventricular tachyarrhythmias: is the implantable cardioverter-defibrillator a primary alternative or merely complementary?
In considering alternatives to the implantable cardioverter-defibrillator (ICD) in patients with malignant ventricular arrhythmias, both pharmacologic and nonpharmacologic therapies are available. Unfortunately, both pharmacologic methods (even when therapy is individualized and optimized) and nonpharmacologic methods (including coronary revascularization and radiofrequency or surgical ablation) yield long-term results that are unacceptable for many patients. Thus, the ICD should be strongly considered as complementary therapy, even when alternative methods are selected. More importantly, early implantation of an ICD often may be justified as the first therapeutic alternative, rather than as complementary therapy, in patients with life-threatening ventricular arrhythmias.
Capucci
A
A
Divisione di Cardiologia, Ospedale Civile, Piacenza, Italy.
Aschieri
D
D
Villani
G Q
GQ
Rosi
A
A
D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use; D003131:Combined Modality Therapy; D017147:Defibrillators, Implantable; D006801:Humans; D017180:Tachycardia, Ventricular / Q000628:therapy*
D000889:Anti-Arrhythmia Agents